Recent years have witnessed significant developments in the field of diabetes treatment, with a particular focus on GLP-1 receptor agonists. Among these novel therapies, retatrutide and trizepatide are emerging as https://woodyuyck008055.csublogs.com/46520727/novel-therapeutic-targets-in-diabetes-retatrutide-and-trizepatide